Total Funding
4
50
Total FundingEquity Crowdfunding raised
Growth Score
0 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
148243
SynAgile offers DopaFuse, an infusion therapy to stabilize L-DOPA levels in the body for patients who suffer from Parkinson’s disease.
- Ephraim Heller: Cofounder, CEO and ChairmanPast Role: TheraSense, Cofounder, CEO, VP
- Jennifer Harmon: Director, Clinical Affairs
About the Company
SynAgile™ is dedicated to transforming the treatment of L-DOPA-responsive motor and non-motor complications in patients with Parkinson's disease. Our novel drugs and routes of administration are designed to enable patients to achieve stable plasma L-DOPA concentrations, and to provide convenient, continuous dopaminergic stimulation.
